Skip to main content
Erschienen in: Pathology & Oncology Research 2/2020

13.04.2019 | Original Article

Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma

verfasst von: Chenggang Yang, Di Huang, Cui Ma, Jing Ren, Lina Fu, Cheng Cheng, Bangling Li, Xiaofeng Shi

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma (OS) is an aggressive malignant tumor of the bones. Our study intended to identify and analyze potential pathogenic genes and upstream regulators for OS. We performed an integrated analysis to identify candidate pathogenic genes of OS by using three Gene Expression Omnibus (GEO) databases (GSE66673, GSE49003 and GSE37552). GO and KEGG enrichment analysis were utilized to predict the functional annotation and potential pathways of differentially expressed genes (DEGs). The OS-specific transcriptional regulatory network was established to study the crucial transcriptional factors (TFs) which target the DEGs in OS. From the three GEO datasets, we identified 759 DEGs between metastasis OS samples and non-metastasis OS samples. After GO and KEGG analysis, ‘cell adhesion’ (FDR = 1.27E-08), ‘protein binding’ (FDR = 1.13E-22), ‘cytoplasm’ (FDR = 5.63E-32) and ‘osteoclast differentiation’ (FDR = 0.000992221) were significantly enriched pathways for DEGs. HSP90AA1 exhibited a highest degree (degree = 32) and was enriched in ‘pathways in cancer’ and ‘signal transduction’. BMP6, regulated by Pax-6, was enriched in the ‘TGF-beta signaling pathway’. We indicated that BMP6 may be downregulated by Pax-6 in the non-metastasis OS samples. The up-regulated HSP90AA1 and down-regulated BMP6 and ‘pathways in cancer’ and ‘signal transduction’ were deduced to be involved in the pathogenesis of OS. The identified biomarkers and biological process in OS may provide foundation for further study.
Literatur
1.
Zurück zum Zitat Zhou W, Hao M, Du X, Chen K, Wang G, Yang J (2014) Advances in targeted therapy for osteosarcoma. Discov Med 17(96):301–307PubMed Zhou W, Hao M, Du X, Chen K, Wang G, Yang J (2014) Advances in targeted therapy for osteosarcoma. Discov Med 17(96):301–307PubMed
2.
Zurück zum Zitat Bernardini, G., Geminiani, M., Gambassi, S., Orlandini, M., Petricci, E., & Marzocchi, B., et al. (2017). Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. J Cell Physiol Bernardini, G., Geminiani, M., Gambassi, S., Orlandini, M., Petricci, E., & Marzocchi, B., et al. (2017). Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. J Cell Physiol
3.
Zurück zum Zitat Yan H, Zhang B, Fang C, Chen L (2018) Mir-340 alleviates chemoresistance of osteosarcoma cells by targeting zeb1. Anti-Cancer Drugs:1 Yan H, Zhang B, Fang C, Chen L (2018) Mir-340 alleviates chemoresistance of osteosarcoma cells by targeting zeb1. Anti-Cancer Drugs:1
4.
Zurück zum Zitat Pang Y, Zhao J, Fowdur M, Liu Y, Wu H, He M (2018) To explore the mechanism of the grm4 gene in osteosarcoma by rna sequencing and bioinformatics approach. Med Sci Monit Basic Res 24:16–25PubMedPubMedCentral Pang Y, Zhao J, Fowdur M, Liu Y, Wu H, He M (2018) To explore the mechanism of the grm4 gene in osteosarcoma by rna sequencing and bioinformatics approach. Med Sci Monit Basic Res 24:16–25PubMedPubMedCentral
5.
Zurück zum Zitat Mitchell PJ, Tjian R (1989) Transcriptional regulation in mammalian cells by sequence-specific dna binding proteins. Science 245(4916):371–378PubMed Mitchell PJ, Tjian R (1989) Transcriptional regulation in mammalian cells by sequence-specific dna binding proteins. Science 245(4916):371–378PubMed
6.
Zurück zum Zitat Zhu M, Liu CC, Cheng C (2013) Reactin: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics 14(1):504PubMedPubMedCentral Zhu M, Liu CC, Cheng C (2013) Reactin: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics 14(1):504PubMedPubMedCentral
7.
Zurück zum Zitat Yang L, Feng S, Yang Y (2016) Identification of transcription factors (tfs) and targets involved in the cholangiocarcinoma (cca) by integrated analysis. Cancer Gene Ther 23(12):439–445PubMed Yang L, Feng S, Yang Y (2016) Identification of transcription factors (tfs) and targets involved in the cholangiocarcinoma (cca) by integrated analysis. Cancer Gene Ther 23(12):439–445PubMed
8.
Zurück zum Zitat Diao C, Xi Y, Xiao T (2018) Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett 15(3):2789–2794PubMed Diao C, Xi Y, Xiao T (2018) Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett 15(3):2789–2794PubMed
9.
Zurück zum Zitat Liu HY, Zhang CJ (2017) Identification of differentially expressed genes and their upstream regulators in colorectal cancer. Cancer Gene Ther 24:244–250PubMed Liu HY, Zhang CJ (2017) Identification of differentially expressed genes and their upstream regulators in colorectal cancer. Cancer Gene Ther 24:244–250PubMed
10.
Zurück zum Zitat Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300
11.
Zurück zum Zitat Li JJ, Wang BQ, Fei Q, Yang Y, Li D (2016) Identification of candidate genes in osteoporosis by integrated microarray analysis. Bone Joint Res 5(12):594–601PubMed Li JJ, Wang BQ, Fei Q, Yang Y, Li D (2016) Identification of candidate genes in osteoporosis by integrated microarray analysis. Bone Joint Res 5(12):594–601PubMed
12.
Zurück zum Zitat Wang F, Wang R, Li Q, Qu X, Hao Y, Yang J, Zhao H, Wang Q, Li G, Zhang F, Zhang H, Zhou X, Peng X, Bian Y, Xiao W (2017) A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies. Diagn Pathol 12(1):4PubMedPubMedCentral Wang F, Wang R, Li Q, Qu X, Hao Y, Yang J, Zhao H, Wang Q, Li G, Zhang F, Zhang H, Zhou X, Peng X, Bian Y, Xiao W (2017) A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies. Diagn Pathol 12(1):4PubMedPubMedCentral
13.
Zurück zum Zitat Lee YS, Kim JK, Ryu SW, Bae SJ, Kwon K, Noh YH, Kim SY (2015) Integrative meta-analysis of multiple gene expression profiles in acquired gemcitabine-resistant cancer cell lines to identify novel therapeutic biomarkers. Asian Pac J Cancer Prev 16(7):2793–2800PubMed Lee YS, Kim JK, Ryu SW, Bae SJ, Kwon K, Noh YH, Kim SY (2015) Integrative meta-analysis of multiple gene expression profiles in acquired gemcitabine-resistant cancer cell lines to identify novel therapeutic biomarkers. Asian Pac J Cancer Prev 16(7):2793–2800PubMed
14.
Zurück zum Zitat Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 40(4):523–532PubMed Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 40(4):523–532PubMed
15.
Zurück zum Zitat Guan D, Tian H (2017) Integrated network analysis to explore the key genes regulated by parathyroid hormone receptor 1 in osteosarcoma. World J Sugr Oncol 15(1):177 Guan D, Tian H (2017) Integrated network analysis to explore the key genes regulated by parathyroid hormone receptor 1 in osteosarcoma. World J Sugr Oncol 15(1):177
16.
Zurück zum Zitat Taipale M, Jarosz DF, Lindquist S (2010) Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515–528PubMed Taipale M, Jarosz DF, Lindquist S (2010) Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515–528PubMed
17.
Zurück zum Zitat Coskunpinar E, Akkaya N, Yildiz P, Oltulu YM, Aynaci E, Isbir T, Yaylim I (2014) The significance of hsp90aa1, hsp90ab1 and hsp90b1 gene polymorphisms in a turkish population with non-small cell lung cancer. Anticancer Res 34(2):753–757PubMed Coskunpinar E, Akkaya N, Yildiz P, Oltulu YM, Aynaci E, Isbir T, Yaylim I (2014) The significance of hsp90aa1, hsp90ab1 and hsp90b1 gene polymorphisms in a turkish population with non-small cell lung cancer. Anticancer Res 34(2):753–757PubMed
18.
Zurück zum Zitat Chu SH, Liu YW, Zhang L, Liu B, Li L, Shi JZ, Li L (2013) Regulation of survival and chemoresistance by hsp90aa1 in ovarian cancer skov3 cells. Mol Biol Rep 40(1):1–6PubMed Chu SH, Liu YW, Zhang L, Liu B, Li L, Shi JZ, Li L (2013) Regulation of survival and chemoresistance by hsp90aa1 in ovarian cancer skov3 cells. Mol Biol Rep 40(1):1–6PubMed
19.
Zurück zum Zitat Mckay, W., Boden, S., & Yoon, S. (2006). METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS. CA, EP1629106 Mckay, W., Boden, S., & Yoon, S. (2006). METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS. CA, EP1629106
20.
Zurück zum Zitat Honda Y, Knutsen R, Strong DD, Sampath TK, Baylink DJ, Mohan S (1997) Osteogenic protein-1 stimulates mrna levels of bmp-6 and decreases mrna levels of bmp-2 and -4 in human osteosarcoma cells. Calcif Tissue Int 60(3):297–301PubMed Honda Y, Knutsen R, Strong DD, Sampath TK, Baylink DJ, Mohan S (1997) Osteogenic protein-1 stimulates mrna levels of bmp-6 and decreases mrna levels of bmp-2 and -4 in human osteosarcoma cells. Calcif Tissue Int 60(3):297–301PubMed
21.
Zurück zum Zitat Shi, Y. J., & Pan, X. T. (2016). Bmp6 and bmp4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv. Genet Mol Res Gmr, 15(1) Shi, Y. J., & Pan, X. T. (2016). Bmp6 and bmp4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv. Genet Mol Res Gmr, 15(1)
22.
Zurück zum Zitat Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S et al (2015) Bmp-6 inhibits the metastasis of mda-mb-231 breast cancer cells by regulating mmp-1 expression. Oncol Rep 35(3)PubMed Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S et al (2015) Bmp-6 inhibits the metastasis of mda-mb-231 breast cancer cells by regulating mmp-1 expression. Oncol Rep 35(3)PubMed
23.
Zurück zum Zitat Liu G, Liu YJ, Lian WJ, Zhao ZW, Yi T, Zhou HY (2014) Reduced bmp6 expression by dna methylation contributes to emt and drug resistance in breast cancer cells. Oncol Rep 32(2):581–588PubMed Liu G, Liu YJ, Lian WJ, Zhao ZW, Yi T, Zhou HY (2014) Reduced bmp6 expression by dna methylation contributes to emt and drug resistance in breast cancer cells. Oncol Rep 32(2):581–588PubMed
24.
Zurück zum Zitat Zong X, Yang H, Yu Y, Zou D, Ling Z, He X, Meng X (2011) Possible role of pax-6 in promoting breast cancer cell proliferation and tumorigenesis. BMB Rep 44(9):595–600PubMed Zong X, Yang H, Yu Y, Zou D, Ling Z, He X, Meng X (2011) Possible role of pax-6 in promoting breast cancer cell proliferation and tumorigenesis. BMB Rep 44(9):595–600PubMed
25.
Zurück zum Zitat Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL et al (2010) Tumor suppressor pax6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 70(2):190–199PubMedPubMedCentral Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL et al (2010) Tumor suppressor pax6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 70(2):190–199PubMedPubMedCentral
Metadaten
Titel
Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma
verfasst von
Chenggang Yang
Di Huang
Cui Ma
Jing Ren
Lina Fu
Cheng Cheng
Bangling Li
Xiaofeng Shi
Publikationsdatum
13.04.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00645-w

Weitere Artikel der Ausgabe 2/2020

Pathology & Oncology Research 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.